Literature DB >> 29913221

Cell penetrating peptides in ocular drug delivery: State of the art.

S Pescina1, C Ostacolo2, I M Gomez-Monterrey2, M Sala3, A Bertamino3, F Sonvico1, C Padula1, P Santi1, A Bianchera4, S Nicoli5.   

Abstract

Despite the increasing number of effective therapeutics for eye diseases, their treatment is still challenging due to the presence of effective barriers protecting eye tissues. Cell Penetrating Peptides (CPPs), synthetic and natural short amino acid sequences able to cross cellular membrane thanks to a transduction domain, have been proposed as possible enhancing strategies for ophthalmic delivery. In this review, a general description of CPPs classes, design approaches and proposed cellular uptake mechanisms will be provided to the reader as an introduction to ocular CPPs application, together with an overview of the main problems related to ocular administration. The results obtained with CPPs for the treatment of anterior and posterior segment eye diseases will be then introduced, with a focus on non-invasive or minimally invasive administration, shifting from CPPs capability to obtain intracellular delivery to their ability to cross biological barriers. The problems related to in vitro, ex vivo and in vivo models used to investigate CPPs mediated ocular delivery will be also addressed together with potential ocular toxicity issues.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Cell penetrating peptides; Cellular uptake; Cornea; Delivery; Eye drop; HCE: human corneal epithelial cell; In vitro models; Intravitreal injection; Ocular Drug; Ocular barriers; PEP-1; POD; Penetratin; Peptide for ocular delivery; Posterior eye segment; TAT; Topical instillation

Mesh:

Substances:

Year:  2018        PMID: 29913221     DOI: 10.1016/j.jconrel.2018.06.023

Source DB:  PubMed          Journal:  J Control Release        ISSN: 0168-3659            Impact factor:   9.776


  14 in total

1.  Peptide Inhibitors of MARCKS Suppress Endotoxin Induced Uveitis in Rats.

Authors:  Tara Stonex; Jacklyn H Salmon; Kenneth B Adler; Brian C Gilger
Journal:  J Ocul Pharmacol Ther       Date:  2022-04       Impact factor: 2.850

2.  Fluoroalkylation promotes cytosolic peptide delivery.

Authors:  Guangyu Rong; Changping Wang; Lijie Chen; Yang Yan; Yiyun Cheng
Journal:  Sci Adv       Date:  2020-08-12       Impact factor: 14.136

Review 3.  Peptidomimetics Therapeutics for Retinal Disease.

Authors:  Dylan E Parsons; Soo Hyeon Lee; Young Joo Sun; Gabriel Velez; Alexander G Bassuk; Mark Smith; Vinit B Mahajan
Journal:  Biomolecules       Date:  2021-02-24

4.  Co-Delivery Of Dihydroartemisinin And HMGB1 siRNA By TAT-Modified Cationic Liposomes Through The TLR4 Signaling Pathway For Treatment Of Lupus Nephritis.

Authors:  Lu Diao; Jin Tao; Yiqi Wang; Ying Hu; Wenfei He
Journal:  Int J Nanomedicine       Date:  2019-11-04

Review 5.  Nasal Drug Delivery of Anticancer Drugs for the Treatment of Glioblastoma: Preclinical and Clinical Trials.

Authors:  Franciele Aline Bruinsmann; Gustavo Richter Vaz; Aline de Cristo Soares Alves; Tanira Aguirre; Adriana Raffin Pohlmann; Silvia Stanisçuaski Guterres; Fabio Sonvico
Journal:  Molecules       Date:  2019-11-26       Impact factor: 4.411

6.  Redox-Responsive Hyaluronic Acid-Based Nanogels for the Topical Delivery of the Visual Chromophore to Retinal Photoreceptors.

Authors:  Amine M Laradji; Alexander V Kolesnikov; Bedia B Karakoçak; Vladimir J Kefalov; Nathan Ravi
Journal:  ACS Omega       Date:  2021-02-22

7.  The Use of TAT Peptide-Functionalized Graphene as a Highly Nuclear-Targeting Carrier System for Suppression of Choroidal Melanoma.

Authors:  Suyan Shan; Shujuan Jia; Tom Lawson; Lu Yan; Mimi Lin; Yong Liu
Journal:  Int J Mol Sci       Date:  2019-09-10       Impact factor: 5.923

8.  Optimized Conjugation of Fluvastatin to HIV-1 TAT Displays Enhanced Pro-Apoptotic Activity in HepG2 Cells.

Authors:  Lamya H Al-Wahaibi; Muneera S M Al-Saleem; Osama A A Ahmed; Usama A Fahmy; Nabil A Alhakamy; Basma G Eid; Ashraf B Abdel-Naim; Wael M Abdel-Mageed; Maha M AlRasheed; Gamal A Shazly
Journal:  Int J Mol Sci       Date:  2020-06-10       Impact factor: 5.923

9.  Dexmedetomidine and levobupivacaine co-loaded, transcriptional transactivator peptide modified nanostructured lipid carriers or lipid-polymer hybrid nanoparticles, which performed better for local anesthetic therapy?

Authors:  Min Li; Shuo Feng; Huaixin Xing; Yingui Sun
Journal:  Drug Deliv       Date:  2020-12       Impact factor: 6.419

Review 10.  The Emerging Role of Topical Ocular Drugs to Target the Posterior Eye.

Authors:  Lixiang Wang; Mikael Ben Zhou; Hui Zhang
Journal:  Ophthalmol Ther       Date:  2021-07-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.